Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million settlement with American authorities. It has risen for two consecutive weeks,

There was some good news in the clinical sphere for Gilead Sciences (NASDAQ: GILD) on Thursday, and this drove its stock price up by almost 3% that trading session. A late-stage clinical trial of an investigational drug yielded encouraging initial results, hence the rise. In comparison, the S&P 500 index inched up by 0.8% on the day.